Logos Global Management’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.02M | Buy |
350,000
+110,000
| +46% | +$2.21M | 0.78% | 32 |
|
|
2025
Q1 | $4.72M | Buy |
240,000
+100,000
| +71% | +$1.97M | 0.84% | 26 |
|
|
2024
Q4 | $3.15M | Sell |
140,000
-355,000
| -72% | -$7.99M | 0.37% | 43 |
|
|
2024
Q3 | $12.6M | Sell |
495,000
-100,000
| -17% | -$2.55M | 1.36% | 24 |
|
|
2024
Q2 | $13.9M | Sell |
595,000
-979,220
| -62% | -$22.9M | 1.12% | 25 |
|
|
2024
Q1 | $26.4M | Buy |
1,574,220
+1,267,144
| +413% | +$21.3M | 2.14% | 14 |
|
|
2023
Q4 | $4.25M | Hold |
307,076
| – | – | 0.4% | 39 |
|
|
2023
Q3 | $4.19M | Hold |
307,076
| – | – | 0.56% | 38 |
|
|
2023
Q2 | $6.27M | Sell |
307,076
-94,153
| -23% | -$1.92M | 0.85% | 34 |
|
|
2023
Q1 | $8.79M | Buy |
+401,229
| New | +$8.79M | 1.26% | 30 |
|